FDA Office of Oncology Drug Products Names New President
May 11, 2005
Dr. Richard Pazdur was named as the first Director of the Food and Drug Administration’s (FDA) new Office of Oncology Drug Products. He has been part of the FDA for the past five years and currently heads the Division of Oncology Drug Products. Prior to joining the FDA, Dr. Pazdur was a tenured Professor of Medicine and Assistant Vice President for Academic Affairs at the M.D. Anderson Cancer Center at the University of Texas.
The Office of Oncology Drug Products is within the Center for Drug Evaluation and Research (CDER). Currently, new oncology drug applications are handled by people in at least three different divisions who report to directors of three different offices. By housing the offices under one director the review process will reflect an improved timeliness and consistency.
The office will include the review process of pharmaceuticals for the prevention, diagnosis and treatment of cancer. As always, the safety of the process will be of utmost importance. It is hoped the new office will facilitate more collaboration with the National Cancer Institute (NCI), as well as other government and non-government organizations concerned about cancer. The Office of Oncology Drug Products is slated to begin operations in July.
The appointment has the endorsement of the American Society for Clinical Oncology and the National Coalition for Cancer Survivorship. The National Children’s Cancer Society applauds this appointment and is pleased with the role of pediatric drug approvals in this new office.
<< Back
May 11, 2005
Dr. Richard Pazdur was named as the first Director of the Food and Drug Administration’s (FDA) new Office of Oncology Drug Products. He has been part of the FDA for the past five years and currently heads the Division of Oncology Drug Products. Prior to joining the FDA, Dr. Pazdur was a tenured Professor of Medicine and Assistant Vice President for Academic Affairs at the M.D. Anderson Cancer Center at the University of Texas.The Office of Oncology Drug Products is within the Center for Drug Evaluation and Research (CDER). Currently, new oncology drug applications are handled by people in at least three different divisions who report to directors of three different offices. By housing the offices under one director the review process will reflect an improved timeliness and consistency.
The office will include the review process of pharmaceuticals for the prevention, diagnosis and treatment of cancer. As always, the safety of the process will be of utmost importance. It is hoped the new office will facilitate more collaboration with the National Cancer Institute (NCI), as well as other government and non-government organizations concerned about cancer. The Office of Oncology Drug Products is slated to begin operations in July.
The appointment has the endorsement of the American Society for Clinical Oncology and the National Coalition for Cancer Survivorship. The National Children’s Cancer Society applauds this appointment and is pleased with the role of pediatric drug approvals in this new office.
<< Back
